ClinVar Miner

Submissions for variant NM_198428.3(BBS9):c.2381A>G (p.Asn794Ser)

gnomAD frequency: 0.00001  dbSNP: rs774701632
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001202522 SCV001373635 uncertain significance Bardet-Biedl syndrome 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 794 of the BBS9 protein (p.Asn794Ser). This variant is present in population databases (rs774701632, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with BBS9-related conditions. ClinVar contains an entry for this variant (Variation ID: 934179). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BBS9 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002484085 SCV002787231 uncertain significance Bardet-Biedl syndrome 9 2022-02-05 criteria provided, single submitter clinical testing
Ambry Genetics RCV003346356 SCV004052771 uncertain significance Inborn genetic diseases 2023-08-15 criteria provided, single submitter clinical testing The c.2381A>G (p.N794S) alteration is located in exon 21 (coding exon 20) of the BBS9 gene. This alteration results from a A to G substitution at nucleotide position 2381, causing the asparagine (N) at amino acid position 794 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003405384 SCV004107847 uncertain significance BBS9-related condition 2024-01-02 criteria provided, single submitter clinical testing The BBS9 c.2381A>G variant is predicted to result in the amino acid substitution p.Asn794Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.052% of alleles in individuals of Latino descent in gnomAD, which may be too common to be the primary cause of disease. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.